tupungato
tupungato / iStockphoto.com
12 July 2017Big Pharma

Actavis v Eli Lilly: UK Supreme Court updates patent infringement test

The UK Supreme Court has reformulated the three questions that should be asked when testing for equivalent patent infringement.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
16 July 2020   As the UK Supreme Court reverses a Court of Appeal decision relating to sufficiency, the ruling leaves patent applicants in a potentially difficult position, argues David Fyfield of Charles Russell Speechlys.
Big Pharma
7 July 2017   The UK Supreme Court has ruled that Actavis’s generic versions of cancer drug Alimta directly infringe patents owned by Eli Lilly, reversing two earlier decisions.
Americas
11 October 2018   Eli Lilly has filed a complaint against France-based biotechnology company Adocia over patents relating to fast-acting insulin.

More on this story

Biotechnology
16 July 2020   As the UK Supreme Court reverses a Court of Appeal decision relating to sufficiency, the ruling leaves patent applicants in a potentially difficult position, argues David Fyfield of Charles Russell Speechlys.
Big Pharma
7 July 2017   The UK Supreme Court has ruled that Actavis’s generic versions of cancer drug Alimta directly infringe patents owned by Eli Lilly, reversing two earlier decisions.
Americas
11 October 2018   Eli Lilly has filed a complaint against France-based biotechnology company Adocia over patents relating to fast-acting insulin.

More on this story

Biotechnology
16 July 2020   As the UK Supreme Court reverses a Court of Appeal decision relating to sufficiency, the ruling leaves patent applicants in a potentially difficult position, argues David Fyfield of Charles Russell Speechlys.
Big Pharma
7 July 2017   The UK Supreme Court has ruled that Actavis’s generic versions of cancer drug Alimta directly infringe patents owned by Eli Lilly, reversing two earlier decisions.
Americas
11 October 2018   Eli Lilly has filed a complaint against France-based biotechnology company Adocia over patents relating to fast-acting insulin.